Genitourinary Pathogen Detection Panel Testing

UnitedHealthcare Commercial Medical Policy Genitourinary Pathogen Nucleic Acid Detection Panel Testing Policy Number: 2021T0608D. Effective Date: April 1, 2021 Instructions for Use Table of Contents Page Community Plan Policy Coverage Rationale .. 1 Genitourinary Pathogen Nucleic Acid Detection Definitions .. 1 Panel Testing Applicable Codes .. 2. Description of Services .. 2. Clinical Evidence .. 3. Food and Drug Administration .. 8. References .. 8. Policy History/Revision Information .. 10. Instructions for Use .. 10. Coverage Rationale The following are proven and medically necessary to evaluate symptomatic women for Vaginitis: Direct and amplified DNA probe Testing for Trichomoniasis vaginalis Direct probe Testing for Candida sp Due to insufficient evidence of efficacy, the following are unproven and not medically necessary: Amplified DNA probe Testing for vulvovaginitis due to Candida sp Direct and amplified DNA probe Testing for bacterial Vaginosis ( , Gardnerella vaginalis).

Infectious disease, bacterial vaginosis, quantitative real-time amplification of RNA markers for ... Molecular testing for diagnosis of vaginal infection is based on the detection of one or more specific nucleic acid sequences. In . ... small number of cases and therefore is an inconsistent diagnostic feature (Huppert, 2009).

Loading..

Tags:

  Testing, Disease, Infectious, Molecular, Diagnostics, Infectious disease, Molecular testing

Information

Related search queries